Breakthrough Combination Immunotherapy for Rare Cancers

Bristol Myers Squibb (BMS) has achieved a significant milestone in the field of rare cancers with its combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab), two of its leading immuno-oncology drugs. The S1609 DART Phase 2 trial, led by the National Cancer Institute (NCI) and the SWOG Cancer Research Network, involved 798 patients with 53 different rare cancer types. The final results revealed that 24 of the 45 cohorts (45%) showed meaningful clinical activity, with an overall objective response rate (ORR) of 12% and a clinical benefit rate (CBR) of 27%. This combination therapy offers a powerful alternative, particularly for patients with rare cancers that have limited or no standard treatment options, and has garnered significant attention in the market.

Maximizing Clinical Efficiency Through Basket Trial Design

The DART trial successfully demonstrated the effectiveness of the basket trial design, which combines multiple rare cancer types into a single clinical framework. Given the difficulty in recruiting patients for rare cancers, conducting individual clinical trials for each cancer type is often impractical due to cost and time constraints. The researchers ingeniously evaluated various rare tumor cohorts simultaneously under a single protocol, significantly reducing clinical costs. Notably, the angiosarcoma cohort showed a response rate of 25%, and the cohort of patients with primary tumors located on the scalp or face achieved an impressive response rate of 60%. This is expected to serve as a benchmark for pharmaceutical companies developing rare disease pipelines, maximizing the probability of clinical success.

BMS's Strategy to Prepare for Patent Expiry Through Expanded Indications

This trial is closely linked to BMS's (ticker: BMY) mid- to long-term portfolio defense strategy. With Opdivo, a key revenue driver, facing a major patent expiry in the late 2020s, the company is facing the urgent task of diversifying new revenue streams and extending the product lifecycle. Although this DART trial is not a direct commercial trial for BMS, the company has secured a strategic advantage by establishing a legitimate basis for off-label prescriptions of its products through a drug supply partnership. As a result, it is expected to maintain Opdivo's global annual revenue of $10 billion in 2025 and strengthen its defense against competing immuno-oncology drugs, such as Merck's Keytruda, in the market.

Securing Prescriptive Evidence and Commercial Viability in a Market with No Standard Treatment

The global market for rare cancer treatments exceeds $130 billion annually and is growing rapidly at approximately 8-10% per year. The results of this Phase 2 trial will play a key role in facilitating the inclusion of the therapy in guidelines such as the National Comprehensive Cancer Network (NCCN), bypassing the rigorous approval process of the U.S. Food and Drug Administration (FDA). This provides clinicians with strong clinical evidence to prescribe the combination of nivolumab and ipilimumab off-label. In the rare cancer market, where there is a high level of unmet medical needs, inclusion in recognized guidelines is a highly efficient commercialization strategy that minimizes marketing costs while securing actual prescription market share.

This Phase 2 basket trial provides a key benchmark for addressing unmet needs in the $130 billion global rare cancer market. From an investor's perspective, it confirms BMS's strategic defense mechanism to extend the product lifecycle of Opdivo, which generated $10 billion in annual revenue in 2025, by expanding new indications in preparation for patent expiry. From the perspective of researchers and industry professionals, it demonstrates that dual immuno-oncology therapy can be an effective treatment option for rare cancer types in the face of strong competition from drugs such as Merck's Keytruda. In the short term, it will stimulate off-label prescriptions through inclusion in the NCCN guidelines, and in the medium to long term, it will have a significant impact on the development of subsequent pipelines based on companion diagnostics and biomarker discovery.